Roche to Acquire Fibrosis-Focused Promedior Acquisitions, Business, Fibrotic Diseases, Human Pentraxin-2 (PTX-2) Protein, Idiopathic Pulmonary Fibrosis (IPF), Immunomodulator Drugs, Lung Functions, Myelofibrosis (MF), Product Pipeline A year after Bristol-Myers Squibb walked away from acquiring Promedior and the company’s fibrotic treatment portfolio, Roche stepped in to acquire the biotech firm for up to $1.4 billion. Read more November 15, 2019/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2019-11-15 12:41:572019-11-15 13:07:06Roche to Acquire Fibrosis-Focused Promedior
